- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04710485
Sphenoorbital Meningioma Management.
January 13, 2021 updated by: Mostafa metwally kashef ali, Assiut University
Spheno_orbital Meningioma Enplaque With Proptosis; Surgical Techniques and Outcomes
Investigators will discuss the different surgical techniques for removal of spheno_orbital meningiomas with proptosis.investigators
also will follow up the patient to know the outcome of removal of these tumours.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
24
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mostafa Mk Kashef, Assistant lecturer
- Phone Number: 01012962093
- Email: mostafakashef99@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 90 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Any patient candidate for surgery will be included in our study.
Description
Inclusion Criteria:
- all patients who have spheno_orbital meningioma with proptosis and candidate for surgery.
Exclusion Criteria:
- all patients have proptosis caused by other lesions than spheno_orbital meningioma.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical assessment for vision.
Time Frame: For 6 months
|
With visual acuity examination
|
For 6 months
|
Clinical assessment for proptosis
Time Frame: For 6 months
|
With proptosis index
|
For 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Assiut Au University, Assiut University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
January 30, 2021
Primary Completion (ANTICIPATED)
December 20, 2022
Study Completion (ANTICIPATED)
January 1, 2023
Study Registration Dates
First Submitted
January 12, 2021
First Submitted That Met QC Criteria
January 13, 2021
First Posted (ACTUAL)
January 14, 2021
Study Record Updates
Last Update Posted (ACTUAL)
January 14, 2021
Last Update Submitted That Met QC Criteria
January 13, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mng
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Meningioma
-
University Hospital, MontpellierCentre Hospitalier Universitaire de BesanconRecruitingAtypical Meningioma | Anaplastic Meningioma | Clear-cell Meningioma | Chordoid Meningioma | Rhabdoid Meningioma | Papillary MeningiomaFrance
-
National Cancer Institute (NCI)CompletedRecurrent Adult Brain Tumor | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Meningeal Hemangiopericytoma | Adult Meningioma | Adult Grade III MeningiomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); NovoCure Ltd.RecruitingAtypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial MeningiomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingGrade 1 Meningioma | Grade 2 Meningioma | Grade 3 Meningioma | Recurrent Meningioma | Unresectable MeningiomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...NovartisTerminatedBrain Metastasis | Recurrent Glioma | High-grade MeningiomaUnited States
-
Nancy Ann Oberheim Bush, MDMerck Sharp & Dohme LLCRecruitingRecurrent Meningioma | Grade I Meningioma, Adult | Grade II Meningioma, Adult | Grade III Meningioma, AdultUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingSchwannoma | Grade III Meningioma | Intracranial Neoplasm | Nerve Sheath Neoplasm | Grade II Meningioma | Grade I Meningioma | Pituitary Gland AdenomaUnited States
-
National Cancer Institute (NCI)RecruitingGrade 2 Meningioma | Grade 3 Meningioma | Recurrent MeningiomaUnited States
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Grade III MeningiomaUnited States
-
University of NebraskaChimerixNot yet recruitingMeningioma | Refractory Meningioma | Relapsed MeningiomaUnited States